figshareBrowse
pone.0247860.g002.tif (1.27 MB)
Download file

Scatter plot of incremental cost against QALY gained by EGFR mutation-guided afatinib versus empirical chemotherapy.

Download (1.27 MB)
figure
posted on 2021-03-01, 18:33 authored by Joyce H. S. You, William C. S. Cho, Wai-kit Ming, Yu-chung Li, Chung-kong Kwan, Kwok-hung Au, Joseph Siu-kie Au

QALY: quality-adjusted life-year; WTP: willingness-to-pay.

History

Usage metrics

Read the peer-reviewed publication

EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong – A cost-effectiveness analysis
PLOS ONEPLOS ONE

Categories

Keywords

WTPConclusions EGFR mutation-guided er...GDPEGFR mutation-guided useTKIepidermal growth factor receptorIIIBModel outcome measuresICERcost-effectiveness analysis Introdu...EGFR mutation-guided erlotinibstrategyun-tested EGFR-sensitizing mutation...Hong KongNSCLCQALYEmpirical first-line chemotherapyUSDnon-small-cell lung cancerResults Empirical chemotherapyEGFR mutation-guided gefitinibEGFR mutation-guided afatinibEGFR mutation-guided target therapy

Licence

CC BY 4.0

Exports